Truist Securities Maintains Hold on Inari Medical, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Inari Medical (NASDAQ:NARI) and raises the price target from $60 to $65.
November 02, 2023 | 7:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a 'Hold' rating on Inari Medical and raises the price target from $60 to $65.
The news is directly related to Inari Medical (NARI). The 'Hold' rating suggests that the analyst believes the stock will perform in line with the market in the near term. The increase in price target from $60 to $65 indicates a positive outlook for the stock, but it may not have a significant impact on the stock's price in the short term as the rating remains 'Hold'.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100